Jefferies stays Buy on Supernus Pharmaceuticals (SUPN) as weekly scripts near 'historical levels'

March 23, 2026 3:11 PM

Jefferies analyst Andrew Tsai reiterated a Buy rating and $65.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN)The analyst commented, "Following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found